PubMed:35477563 / 988-1304 JSONTXT

Annnotations TAB JSON ListView MergeView

    Inflammaging

    {"project":"Inflammaging","denotations":[{"id":"T9","span":{"begin":0,"end":316},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":316},"obj":"Sentence"}],"text":"This study is a monocentric, randomized, double blind, controlled clinical study to investigate the effectiveness of daily adjuvant use of Limosilactobacillus reuteri (Prodentis®-lozenges, DSM 17938, ATCC PTA 5289) versus control lozenges during the first three months of orthodontic treatment with fixed appliances."}

    maxiaofeng52_800_3

    {"project":"maxiaofeng52_800_3","denotations":[{"id":"T7","span":{"begin":139,"end":166},"obj":"CI"}],"text":"This study is a monocentric, randomized, double blind, controlled clinical study to investigate the effectiveness of daily adjuvant use of Limosilactobacillus reuteri (Prodentis®-lozenges, DSM 17938, ATCC PTA 5289) versus control lozenges during the first three months of orthodontic treatment with fixed appliances."}

    wangzhuo19_800_3

    {"project":"wangzhuo19_800_3","denotations":[{"id":"T7","span":{"begin":139,"end":166},"obj":"CI"}],"text":"This study is a monocentric, randomized, double blind, controlled clinical study to investigate the effectiveness of daily adjuvant use of Limosilactobacillus reuteri (Prodentis®-lozenges, DSM 17938, ATCC PTA 5289) versus control lozenges during the first three months of orthodontic treatment with fixed appliances."}